From: Dr. Stephen Noga [Snoga@lifebridgehealth.org]
Sent: Friday, June 14, 2002 4:26 PM
To: FDADockets@oc.fda.gov
Cc: Vasconcells@cber.fda.gov; Celltherapy@earthlink.net;
Davisja@jhmi.edu; Lbuckler@malachite-mgmt.com; Lisa@malachite-mgmt.com;
Ombuds@oc.fda.gov
Subject: Combination Products Containing Live Cellular Components

To whom it may concern:
This is in regard to the Public Hearing sceduled for the above topic on June 24th,2002. Representatives of the International Society for Cellular Therapy (ISCT) request participation in this public hearing. This society represents scientitsts, clinicians, regulatory individuals and technologists working in the somatic cell therapy field in the U.S. and internationally. Please let me know if an agenda is generated for this meeting.
Sincerely
Stephen J. Noga, MD,Ph.D.
President, ISCT
(Full contact information below)

Stephen J. Noga, MD, Ph.D.
Director, Hematology/Medical Oncology
Director, BMT & Cellular Therapeutics Program
Alvin & Lois Lapidus Cancer Institute
Sinai Hospital of Baltimore
2401 West Belvedere Avenue
Baltimore, MD  21215  U.S.A.

T: 410 601 4710
F: 410 601 8448
vmail: 410 601 4605
home email: nogast@comcast.net